Profil
Lisa M.
Bell worked as a Senior Director-Regulatory & Safety at Abbott Biotherapeutics Corp.
and as the Head-Regulatory & Pharmacovigilance at BioMarin Pharmaceutical, Inc. She was also the Senior Vice President- Global Regulatory Affairs at Coherus BioSciences, Inc. from 2014 to 2017.
Bell received her undergraduate and graduate degrees from Boston University and her doctorate from the University of California, Berkeley.
Ehemalige bekannte Positionen von Lisa M. Bell
| Unternehmen | Position | Ende |
|---|---|---|
| COHERUS ONCOLOGY, INC. | General Counsel | 01.12.2017 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Develops antibody therapeutics for the treatment of oncology and immunologic diseases | General Counsel | - |
| BIOMARIN PHARMACEUTICAL INC. | General Counsel | - |
Ausbildung von Lisa M. Bell
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
BioMarin Pharmaceutical, Inc.
BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Develops antibody therapeutics for the treatment of oncology and immunologic diseases | Health Technology |
Boston University
Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Coherus BioSciences, Inc.
Coherus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a commercial-stage biopharmaceutical company that engages in research, development and commercialization of immunotherapies to treat cancer | Health Technology |
















